Neuren Pharmaceuticals Limited (NURPF.OB) reported a profit for full year that Dropped, from the same period last year
The company's bottom line totaled A$30.44 million, or A$0.2327 per share. This compares with A$142.04 million, or A$1.0861 per share, last year.
The company's revenue for the period fell 69.7% to A$64.63 million from A$213.24 million last year.
Neuren Pharmaceuticals Limited earnings at a glance (GAAP) :
-Earnings: A$30.44 Mln. vs. A$142.04 Mln. last year.-EPS: A$0.2327 vs. A$1.0861 last year.-Revenue: A$64.63 Mln vs. A$213.24 Mln last year.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.